Anti-BCMA 1XX-enhanced CAR T-cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of T-lymphocytes that are genetically modified and clustered regularly interspaced short palindromic repeats (CRISPR)-edited to contain an insertion of a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-BCMA 1XX-enhanced CAR-T cells recognize and bind to BCMA-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of BCMA-positive tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) and member of the tumor necrosis factor receptor superfamily (TNFRSF), is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. It plays a key role in plasma cell proliferation and survival. 1XX CAR T-cells bear inactivating point mutations in the two distal immunoreceptor tyrosine-based activation motifs (ITAMs) and retain one functional proximal ITAM in the intracellular signaling domain of the CAR. This may help prevent counterproductive T-cell differentiation and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells.

**Synonyms:** - 1XX BCMA CAR-T Cells - 1XX-enhanced Anti-BCMA CAR T-cells - Anti-BCMA 1XX CAR-T Cells